Clinical application of FDG-PET/CT in metastatic infections

Ilse Johanna Elsa Kouijzer, F.J. Vos, Chantal P. Bleeker-Rovers, W.J.G. Oyen

Research output: Contribution to journalArticleAcademicpeer-review

6 Citations (Scopus)

Abstract

FDG-PET/CT has proven its clinical value and cost-effectiveness in diagnosing metastatic infections in patients with Gram-positive bacteremia. In identification of metastatic foci, FDG-PET/CT is useful as a screening method when localizing symptoms are absent because it provides whole-body coverage. FDG-PET/CT detects early metabolic activity rather than the late anatomical changes as visualized by computed tomography and magnetic resonance imaging. FDG-PET/CT allows more precise localization of infection within a shorter time span between injection and diagnosis as compared to conventional nuclear imaging. This review focuses on the clinical application of imaging of metastatic infectious diseases, with an emphasis on FDG-PET/CT putting it in perspective with other imaging modalities.
Original languageEnglish
Pages (from-to)232-246
JournalQuarterly journal of nuclear medicine and molecular imaging
Volume61
Issue number2
DOIs
Publication statusPublished - 2017

Fingerprint

Bacteremia
Infection
Cost-Benefit Analysis
Communicable Diseases
Tomography
Magnetic Resonance Imaging
Injections

Keywords

  • IR-101108
  • METIS-317736

Cite this

Kouijzer, Ilse Johanna Elsa ; Vos, F.J. ; Bleeker-Rovers, Chantal P. ; Oyen, W.J.G. / Clinical application of FDG-PET/CT in metastatic infections. In: Quarterly journal of nuclear medicine and molecular imaging. 2017 ; Vol. 61, No. 2. pp. 232-246.
@article{8c3dbc479c5d468d85d7123d2d7eb32b,
title = "Clinical application of FDG-PET/CT in metastatic infections",
abstract = "FDG-PET/CT has proven its clinical value and cost-effectiveness in diagnosing metastatic infections in patients with Gram-positive bacteremia. In identification of metastatic foci, FDG-PET/CT is useful as a screening method when localizing symptoms are absent because it provides whole-body coverage. FDG-PET/CT detects early metabolic activity rather than the late anatomical changes as visualized by computed tomography and magnetic resonance imaging. FDG-PET/CT allows more precise localization of infection within a shorter time span between injection and diagnosis as compared to conventional nuclear imaging. This review focuses on the clinical application of imaging of metastatic infectious diseases, with an emphasis on FDG-PET/CT putting it in perspective with other imaging modalities.",
keywords = "IR-101108, METIS-317736",
author = "Kouijzer, {Ilse Johanna Elsa} and F.J. Vos and Bleeker-Rovers, {Chantal P.} and W.J.G. Oyen",
year = "2017",
doi = "10.23736/S1824-4785.16.02735-7",
language = "English",
volume = "61",
pages = "232--246",
journal = "Quarterly journal of nuclear medicine and molecular imaging",
issn = "1824-4785",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "2",

}

Clinical application of FDG-PET/CT in metastatic infections. / Kouijzer, Ilse Johanna Elsa; Vos, F.J.; Bleeker-Rovers, Chantal P.; Oyen, W.J.G.

In: Quarterly journal of nuclear medicine and molecular imaging, Vol. 61, No. 2, 2017, p. 232-246.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Clinical application of FDG-PET/CT in metastatic infections

AU - Kouijzer, Ilse Johanna Elsa

AU - Vos, F.J.

AU - Bleeker-Rovers, Chantal P.

AU - Oyen, W.J.G.

PY - 2017

Y1 - 2017

N2 - FDG-PET/CT has proven its clinical value and cost-effectiveness in diagnosing metastatic infections in patients with Gram-positive bacteremia. In identification of metastatic foci, FDG-PET/CT is useful as a screening method when localizing symptoms are absent because it provides whole-body coverage. FDG-PET/CT detects early metabolic activity rather than the late anatomical changes as visualized by computed tomography and magnetic resonance imaging. FDG-PET/CT allows more precise localization of infection within a shorter time span between injection and diagnosis as compared to conventional nuclear imaging. This review focuses on the clinical application of imaging of metastatic infectious diseases, with an emphasis on FDG-PET/CT putting it in perspective with other imaging modalities.

AB - FDG-PET/CT has proven its clinical value and cost-effectiveness in diagnosing metastatic infections in patients with Gram-positive bacteremia. In identification of metastatic foci, FDG-PET/CT is useful as a screening method when localizing symptoms are absent because it provides whole-body coverage. FDG-PET/CT detects early metabolic activity rather than the late anatomical changes as visualized by computed tomography and magnetic resonance imaging. FDG-PET/CT allows more precise localization of infection within a shorter time span between injection and diagnosis as compared to conventional nuclear imaging. This review focuses on the clinical application of imaging of metastatic infectious diseases, with an emphasis on FDG-PET/CT putting it in perspective with other imaging modalities.

KW - IR-101108

KW - METIS-317736

U2 - 10.23736/S1824-4785.16.02735-7

DO - 10.23736/S1824-4785.16.02735-7

M3 - Article

VL - 61

SP - 232

EP - 246

JO - Quarterly journal of nuclear medicine and molecular imaging

JF - Quarterly journal of nuclear medicine and molecular imaging

SN - 1824-4785

IS - 2

ER -